GlassScriptPhysician profile
Ahmed Nadeem
NPI 1952332041
$52,829.35
in general payments reported to CMS, 2019-2025
80 companies · $5,137 in 2025
The $5,137 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,995 · 2020: $1,222 · 2021: $4,697 · 2022: $19K · 2023: $13K · 2024: $5,561 · 2025: $5,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $9,360 · Education: $759 · Travel and Lodging: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,207.00 |
| Food and Beverage | $9,360.01 |
| Education | $759.33 |
| Travel and Lodging | $246.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $21,863.75 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astrazeneca Pharmaceuticals LP | $4,384.42 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| Incyte Corporation | $3,350.11 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Sirtex Medical INC | $3,057.36 | 2022-2024 | Sir-Spheres Microspheres |
| Beone Medicines USA, INC. | $1,668.17 | 2025 | Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $1,282.03 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Puma Biotechnology, INC. | $1,259.55 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,194.54 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,170.00 | 2023 | Rybrevant |
| Janssen Biotech, INC. | $986.66 | 2020-2025 | Carvykti, Rybrevant, Erleada |
| Glaxosmithkline, LLC. | $874.93 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $861.99 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $744.22 | 2019-2024 | Padcev, Tukysa, Adcetris |
| Abbvie INC. | $688.95 | 2019-2025 | |
| Eisai INC. | $648.87 | 2019-2025 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $580.48 | 2019-2025 | Padcev, Xospata, Vyloy |
| Beigene, LTD. | $525.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $515.53 | 2019-2025 | Kisqali |
| Merck Sharp & Dohme LLC | $462.94 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $442.82 | 2019-2025 | |
| Genentech USA, INC. | $422.85 | 2019-2025 | Tecentriq, Polivy, Venclexta |
| Lilly USA, LLC | $380.56 | 2019-2025 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $346.86 | 2021-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $265.29 | 2019-2025 | Ultomiris |
| Gilead Sciences, INC. | $260.77 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $259.44 | 2022-2024 | Xpovio |
| Beigene USA, INC. | $240.19 | 2021-2025 | Brukinsa |
| Emd Serono, INC. | $220.54 | 2022-2025 | |
| Mirati Therapeutics, INC. | $215.72 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $213.63 | 2019-2025 | Zepzelca |
| Sobi, INC | $202.15 | 2022-2025 | |
| Tesaro, INC. | $192.00 | 2019 | |
| Array Biopharma INC | $189.94 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Sanofi-Aventis U.S. LLC | $166.98 | 2022-2023 | |
| Genzyme Corporation | $165.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.15 | 2024-2025 | Fruzaqla, Ninlaro |
| Epizyme, INC. | $156.65 | 2020-2021 | |
| Exelixis INC. | $143.75 | 2019-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $136.95 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $126.16 | 2019-2023 | Onivyde, Somatuline Depot |
| Amgen INC. | $111.81 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Agios Pharmaceuticals, INC. | $109.67 | 2022-2025 | Pyrukynd |
| Tg Therapeutics, INC. | $102.37 | 2021-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Tempus Ai, INC | $76.10 | 2024-2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $74.28 | 2023-2025 | |
| Pharmaessentia USA Corporation | $72.49 | 2022-2025 | Besremi |
| Apellis Pharmaceuticals, INC. | $72.04 | 2023-2024 | Empaveli |
| Progenics Pharmaceuticals, INC. | $70.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.80 | 2019-2023 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $63.53 | 2019-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $61.17 | 2021-2023 | Myrisk |
| Stemline Therapeutics INC. | $59.92 | 2023 | Orserdu |
| Taiho Oncology, INC. | $57.55 | 2019-2025 | |
| Telix Pharmaceuticals | $54.58 | 2024-2025 | Illuccix |
| Regeneron Healthcare Solutions, INC. | $52.97 | 2024-2025 | Libtayo |
| Alnylam Pharmaceuticals INC. | $48.77 | 2024-2025 | Givlaari |
| Eusa Pharma (US) LLC | $47.28 | 2021-2022 | |
| Cti Biopharma Corp. | $43.38 | 2022-2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $42.29 | 2025 | Danziten |
| Geron Corporation | $33.30 | 2025 | Rytelo |
| Caris Mpi, INC. | $32.92 | 2025 | Mi Cancer Seek |
| Deciphera Pharmaceuticals INC. | $25.25 | 2024 | Qinlock |
| Fennec Pharmaceuticals, INC. | $24.98 | 2024 | Pedmark |
| Aveo Pharmaceuticals, INC. | $24.08 | 2024 | |
| Morphosys, US INC. | $24.02 | 2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $23.93 | 2025 | Clonoseq |
| Clovis Oncology, INC. | $23.79 | 2019 | |
| Acceleron Pharma, INC. | $23.33 | 2020 | |
| Immunogen, INC. | $21.49 | 2023 | Elahere |
| Tactile Systems Technology INC | $20.07 | 2025 | Flexitouch Plus, Nimbl |
| Mylan Institutional INC. | $18.19 | 2019 | |
| Legend Biotech USA INC. | $16.49 | 2025 | Carvykti |
| Spectrum Pharmaceuticals INC. | $15.88 | 2023 | Rolvedon |
| Helsinn Therapeutics (U.S.), INC. | $15.67 | 2019 | |
| Sumitomo Pharma America, INC. | $14.95 | 2025 | Orgovyx |
| G1 Therapeutics, INC. | $14.84 | 2023 | Cosela |
| Kite Pharma, INC. | $14.29 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $13.16 | 2023 | Sylvant |
| Teva Pharmaceuticals USA, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
Tavalisse $5,525Rezlidhia $5,525Sir-Spheres Microspheres $3,039Tevimbra $1,668Rybrevant $1,344Reblozyl $415Venclexta $372Jakafi $336Opdivo $328Padcev $302Jemperli $249Zejula $248Lynparza $245Carvykti $238Stivarga $234Enhertu $230Lenvima $216Krazati $216Ojjaara $197Brukinsa $192Epkinly $178Calquence $178Kisqali $161Imbruvica $160Nubeqa $151Braftovi $143Mektovi $143Monjuvi $142Erleada $139Keytruda $138Fruzaqla $137Vitrakvi $132Ultomiris $129Jevtana $122Tecentriq $119Xofigo $118Ziihera $114Lorbrena $113Xpovio $113Illuccix $109Xtandi $103Tagrisso $97.09Pyrukynd $94.67Scemblix $91.87Xalkori $89.89Orgovyx $81.01Vonjo $80.83Tukysa $76.97Xt Cdx $76.10Empaveli $72.04Pylarify $70.00Adcetris $66.60Talzenna $66.06Darzalex $64.52Orserdu $59.92Cabometyx $57.00Zynlonta $56.20Ibrance $54.28Zepzelca $54.11Libtayo $52.97Elrexfio $52.90Pluvicto $52.84Opdualag $51.76Trodelvy $51.69Idhifa $51.03Tibsovo $49.84Givlaari $48.77Xospata $47.78Fabhalta $46.47Gavreto $46.43Pomalyst $43.78Besremi $42.53Danziten $42.29Elahere $41.19Datroway $40.35Vyloy $39.75Jaypirca $39.19Verzenio $39.19Welireg $38.55Shingrix $34.86Polivy $33.87Inlyta $33.51Rytelo $33.30Mi Cancer Seek $32.92Inqovi $32.75Lonsurf $32.75Promacta $30.53Sarclisa $27.62Onivyde $27.28Somatuline Depot $27.28Ninlaro $27.01Xgeva $26.89Nplate $26.89Vectibix $26.89Mekinist $26.55Lumakras $25.91Qinlock $25.25Pedmark $24.98Piqray $24.82Fotivda $24.08
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Nadeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.